Company Overview of Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. operates as a drug discovery company. It designs and develops drugs to tackle diseases involving the nervous system and metabolism. The company was founded in 2007 and is based in Welwyn Garden City, United Kingdom.
Welwyn Garden City, AL7 3AX
Founded in 2007
Key Executives for Heptares Therapeutics Ltd.
President of USA Operations
Compensation as of Fiscal Year 2013.
Heptares Therapeutics Ltd. Key Developments
Heptares Initiates Clinical Study with First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimer's Disease
Dec 9 13
Heptares Therapeutics, the GPCR structure-guided drug discovery and development company, announces that it has initiated a Phase 1 clinical study of HTL9936, the first fully selective muscarinic M1 receptor agonist to enter clinical development. HTL9936 is an orally available, small molecule drug candidate discovered using the Heptares GPCR structure-based drug design (SBDD) platform. Heptares plans to develop HTL9936 as a novel treatment for improving cognitive function (memory and thinking abilities) in patients with Alzheimer's disease and other diseases associated with dementia and cognitive impairment. M1 receptor agonism is a well-validated mechanism of action for treating cognitive impairment and a valuable pharmacological profile that the pharmaceutical industry has endeavored to create for decades. The principal challenge has been to engineer selective compounds that activate the M1 receptor subtype without also activating the M(2) or M(3) receptors, which are associated with undesirable side effects. All previous compounds have been discontinued due to inadequate selectivity. Using a new structure-guided approach, Heptares scientists determined the x-ray crystal structure of the M1 receptor for the first time and leveraged unique insights into the receptor to identify new chemistries with fully selective M1 agonist profiles. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of HTL9936. In addition, the clinical pharmacodynamics of the drug will be investigated in a series of studies over the next year. This study aims to recruit more than 100 healthy volunteers including elderly people at a single clinical centre in the UK. Initial results are expected in mid-2014.
Heptares Therapeutics Ltd. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-06-2013 11:15 AM
Oct 7 13
Heptares Therapeutics Ltd. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-06-2013 11:15 AM. Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria. Speakers: Barry Kenny, Chief Business Officer, Malcolm Weir, Chief Executive Officer.
Heptares Therapeutics Ltd. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-12-2013 through Nov-13-2013
Sep 25 13
Heptares Therapeutics Ltd. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-12-2013 through Nov-13-2013. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Presentation Date & Speakers: Nov-12-2013, Malcolm Weir, Chief Executive Officer. Nov-13-2013, Daniel Grau, President of USA Operations.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 27, 2013